|
Recurrent ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, we found that lower TAZ level in chemo-resistant recurrent ovarian cancer is responsible for reduced ferroptosis susceptibility.
|
31641008 |
2020 |
|
Anaplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dedifferentiation in LS shifts the expression of TIMPs from type 4 to type 1, inducing more aggressive behavior and poor prognosis through YAP/TAZ activation, which can be prognostic markers and therapeutic targets for LS patients.
|
31074490 |
2019 |
|
Bone Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In summary, this study suggests for the first time that Sal B targets TAZ to facilitate osteogenesis and reduce adipogenesis by activating MEK-ERK signalling pathway, which provides evidence for Sal B to be used as a potential therapeutic agent for the management of bone diseases.
|
30907511 |
2019 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In recent years, many studies have reported upregulation or nuclear localization of YAP/TAZ in a number of human malignancies, such as breast cancer, melanoma, lung cancer, especially squamous cell carcinoma in different organs.
|
31360073 |
2019 |
|
liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dedifferentiation in LS shifts the expression of TIMPs from type 4 to type 1, inducing more aggressive behavior and poor prognosis through YAP/TAZ activation, which can be prognostic markers and therapeutic targets for LS patients.
|
31074490 |
2019 |
|
Liver Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A significant decrease was found in the hepatic expression of the SHH, IHH, and TGF-β1 pathways along with the expression of TAZ in tissue specimens with simple steatosis in comparison with patients affected by NASH cirrhosis and controls.
|
31087761 |
2019 |
|
Primary Malignant Liver Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
The Hippo pathway, with its downstream transcriptional co-activator Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), has a decisive role in the carcinogenesis of primary liver cancer.
|
30717258 |
2019 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
YAP and TAZ act as drivers of melanoma through its interaction with the TEAD family of transcription factors.
|
30662519 |
2019 |
|
Giant Cell Arteritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of WWTR1 has a significant inverse correlation with cumulative survival of GCA patients (p < 0.01).
|
30976198 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we examined the expression pattern of YAP and TAZ in 141 patients with hepatocellular carcinoma keratin 19 positive (HCC K19⁺), hepatocellular carcinoma keratin 19 negative (HCC K19<sup>-</sup>), combined hepatocellular⁻cholangiocarcinoma carcinoma (cHCC-CCA), or cholangiocarcinoma (CCA).
|
30717258 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HepG2 liver cancer cell was used in the present study, and shRNA against TAZ was transfected into HepG2 cell to knockdown TAZ expression.
|
30881030 |
2019 |
|
Congenital contractural arachnodactyly
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
All cHCC-CCA and CCA patients showed high expression levels for YAP and TAZ, while only some patients of the HCC group were positive.
|
30717258 |
2019 |
|
Zika Virus Infection
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
<b>Results & conclusion:</b> ZIKV infection altered the DNA methylation of several genes such as WWTR1 (TAZ) and RASSF1 of Hippo signaling pathway which regulates organ size during brain development, and decreased the expression of several centrosomal-related microcephaly genes, and genes involved in stemness and differentiation in human neural progenitor cells.
|
31234652 |
2019 |
|
Adult Liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dedifferentiation in LS shifts the expression of TIMPs from type 4 to type 1, inducing more aggressive behavior and poor prognosis through YAP/TAZ activation, which can be prognostic markers and therapeutic targets for LS patients.
|
31074490 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HepG2 liver cancer cell was used in the present study, and shRNA against TAZ was transfected into HepG2 cell to knockdown TAZ expression.
|
30881030 |
2019 |
|
Childhood Liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dedifferentiation in LS shifts the expression of TIMPs from type 4 to type 1, inducing more aggressive behavior and poor prognosis through YAP/TAZ activation, which can be prognostic markers and therapeutic targets for LS patients.
|
31074490 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Conclusion: HFD-fed miR-223KO mice develop a full spectrum of NAFLD, representing a clinically relevant mouse NAFLD model; miR-223 plays a key role in controlling steatosis-to-NASH progression by inhibiting hepatic Cxcl10 and Taz expression and may be a therapeutic target for the treatment of NASH.
|
30964207 |
2019 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Yes Associated Protein 1 (YAP) and Transcriptional coactivator with PDZ-Binding Motif (TAZ) have gained notoriety for their ability to drive tumor initiation and progression in a wide variety of cancers, including melanoma.
|
30662519 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of genes controlled by the Hippo downstream transcriptional coactivators YAP (Yes-associated protein 1) and TAZ (WWTR1, WW domain containing transcription regulator 1) is widely deregulated in human cancer including head and neck squamous cell carcinoma (HNSCC).
|
31817001 |
2019 |
|
Gastric Cardia Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The Hippo signaling effector WWTR1 is a metastatic biomarker of gastric cardia adenocarcinoma.
|
30976198 |
2019 |
|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
An improved understanding of the role of YAP/TAZ in tumor immunity is essential for exploring innovative tumor treatments and making further breakthroughs in antitumor immunotherapy.
|
31308148 |
2019 |
|
Eccrine Poroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A WWTR1-NUTM1 fusion was identified in a single lesion of poroma.
|
31145701 |
2019 |
|
Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A significant decrease was found in the hepatic expression of the SHH, IHH, and TGF-β1 pathways along with the expression of TAZ in tissue specimens with simple steatosis in comparison with patients affected by NASH cirrhosis and controls.
|
31087761 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent exciting studies from different laboratories indicate that the activity of the transcriptional co-activators Yes-associated protein (YAP) and WW-domain-containing transcriptional co-activator with PDZ-binding motif (TAZ) play a critical role in the promotion and maintenance of PDAC operating as key downstream target of KRAS signaling.
|
31057295 |
2019 |
|
Poroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A WWTR1-NUTM1 fusion was identified in a single lesion of poroma.
|
31145701 |
2019 |